Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Arrivent
Deal Size : $100.0 million
Deal Type : Collaboration
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
Details : ArriVent will be responsible for clinical development and commercialization of a novel ADC molecule, for oncology indications, that relies on the unique modular platform developed by Aarvik.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 15, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Arrivent
Deal Size : $100.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?